When glycemic control is not achieved with a single glucose-lowering agent, an additional medication can be added, but impact of weight should be considered when choosing the most appropriate glucose-lowering therapies. Studies have demonstrated that in addition to improving glucose and providing primary prevention for CVD, weight loss was consistently observed in patients taking GLP-1 RAs.
While GLP-1 RAs and SGLT2 inhibitors both promote weight loss, GLP-1 RAs are recommended in patients with obesity and overweight with weight-related comorbidities, and even in people without type 2 diabetes. GLP-1 RAs are an effective weight loss medication in many settings, with a greater reduction than is seen with SGLT2 inhibitors. This class is considered to have a high efficacy with regard to A1C reduction, making it an alternative to insulin in some cases.
SGLT2 inhibitors are recommended in patients with established CVD and have shown significant benefit in patients with type 2 diabetes and HF, CVD, and/or CKD. This class of agents has been shown to have an intermediate efficacy with regard to A1C lowering. It does not cause hypoglycemia.
Learn more about type 2 diabetes.
Medscape © 2022 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Anne L. Peters. Fast Five Quiz: Type 2 Diabetes and Obesity and Weight Management - Medscape - May 16, 2022.